Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Sandoz generic Copaxone get US FDA approval for to treat relapsing forms of multiple sclerosis

    Sandoz, a global leader in generic pharmaceuticals and a  subsidiary of Novartis, has received approval from the US Food and Drug Administration (FDA) for Glatopa. Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis. Sandoz, together with Momenta, is proud to be the first company to receive FDA approval for a substitutable generic version of this important therapy.

  • Bacteria use magnetic particles to create 'natural battery'

    Bacteria can use tiny magnetic particles to effectively create a 'natural battery', a new study has found. The bacteria can load electrons onto and discharge electrons from microscopic particles of magnetite, researchers said. This discovery holds out the potential of using this mechanism to help clean up environmental pollution, and other bioengineering applications, they said.

  • Comfortably Numb Device arrest Pain of Drug Injections

    A team of three engineering students from Rice University, Houston, United States, created the device to ease the pain of an injection. A new drug injector called "Comfortably Numb" is a cooling device. It numbs the skin prior to getting a shot.  It works like an ice pack, which produces a rapid chemical reaction that cools and numbs patients' skin in seconds. The device consists of a small 3D-printed cylinder with a metal plate at one end. It contain ammonium nitrate and water in separate compartments.

  • Aeterna Zentaris plans to conduct phase 3 study of Macrilen in AGHD

    Aeterna Zentaris Inc., a specialty biopharmaceutical company, is planning to conduct a new, confirmatory phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (AGHD), as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarisation.

  • Exelixis’ cabozantinib received Fast Track designation by US FDA for RCC treatment

    The US Food & Drug Administration (FDA) has granted Fast Track designation to Exelixis, Inc's cabozantinib for treatment of patients with advanced renal cell carcinoma (RCC). Cabozantinib is the Exelixis' lead compound . Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer.

Subscribe to Pharma News

Search this website